<DOC>
	<DOCNO>NCT00147225</DOCNO>
	<brief_summary>The goal clinical research study find high safe dose AMG 531 decrease risk severity thrombocytopenia ( low platelet count ) patient receive chemotherapy . Researchers also look safety effectiveness AMG 531 ( Romiplostim ) . Primary Objectives : 1 . To determine clinical safety tolerability AMG 531 administer follow chemotherapy patient advance malignancy 2 . To determine optimal biologic dose ( OBD ) AMG 531 administer patient receive chemotherapy know cause severe thrombocytopenia 3 . To evaluate effect AMG 531 degree duration thrombocytopenia platelet recovery follow chemotherapy Secondary Objective : 1 . To evaluate limited pharmacokinetics AMG 531 administer S.C. route post-chemotherapy</brief_summary>
	<brief_title>AMG 531 Patients With Advanced Malignancy Receiving Treatment With Carboplatin</brief_title>
	<detailed_description>Platelets cell help make blood clot . A decrease platelets cause bleeding , may prevent delay patient receive chemotherapy . Researchers want find AMG 531 low risk severity side effect . AMG 531 protein stimulates platelet production . If eligible take part study , assign 1 6 dosing schedule study drug . The dose AMG 531 receive depend enrol . In Cycle 1 , patient receive chemotherapy . Three ( 3 ) week later , Cycle 2 , dose chemotherapy give follow AMG 531 . AMG 531 give one 3 schedule . AMG 531 give injection skin day chemotherapy 2 day later ; give 5 day day chemotherapy ; give 5 3 day chemotherapy day chemotherapy 2 day later . The schedule receive depend enroll study . After 2 cycle treatment , base response disease tolerance treatment , participant may able receive 4 cycle chemotherapy follow AMG 531 . All participant continue schedule receiving . The dose AMG 531 may increase one time point study base response platelet count . The number blood test draw ( 3 teaspoon ) depend clinical condition . These sample take least 2 time week often day portion study . You also blood ( 1 teaspoon ) collect evaluation anti-AMG 531 antibody status treatment start , end Cycles 2 4 , end study . You take study disease get bad intolerable side effect occur . At end study , medical history physical exam , include measurement vital sign . You also blood ( 1 teaspoon ) drawn routine test . This investigational study . AMG 531 FDA approve commercially available . At time , use research purpose . Up 56 patient take part study . All enrol University Texas ( UT ) MD Anderson .</detailed_description>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>1 . Patients diagnosis solid tumor high risk chemotherapyinduced severe thrombocytopenia relate follow regimen : ( ) Carboplatin ( AUC=11 ) ; ( b ) AI regimen ( adriamycin 7590mg/m2 , Ifosfamide 10gm/m2 ) ; ( c ) High dose Ifosfamide ( 14gm/m2 ) 2 . Age &gt; /= 18 year . 3 . Adequate hematologic ( Absolute neutrophil count ( ANC ) &gt; /= 1500/mm^3 , platelet count &gt; /= 100 x 10^9/L Hgb &gt; /= 8 gm/dL ) , renal ( serum creatinine &lt; /= 2.0 mg/dL ) , hepatic function ( total bilirubin &lt; /= 2 time , aspartate aminotransferase ( AST SGOT ) alanine aminotransferase ( ALT SGPT ) &lt; /= 3 time upper limit respective normal range ) . 4 . Karnofsky Performance Status &gt; /= 80 5 . Signed informed consent form 6 . Patients childbearing potential ( define postmenopausal 12 month previous surgical sterilization ) must negative pregnancy test use adequate birth control . [ i.e . oral contraceptive , spermicide either condom , diaphragm cervical cap , use intrauterine device ( IUD ) , abstinence ] . 1 . Patients rapidly progressive disease ( patient rapidly accumulate ascites pleural effusion ) . 2 . Patients hematologic malignancy . 3 . Pregnant lactating woman . 4 . History central nervous system ( CNS ) metastasis . 5 . Patients significant cardiac disease ( New York Hearth Association ( NYHA ) Class III IV ) , dysrrhythmia , recent history MI ischemia , transient ischemic attack cerebrovascular accident ( CVA ) , within previous 6 month study entry . 6 . Patients history thromboembolic event ( history deep venous thrombosis ( DVT ) pulmonary embolus ) . 7 . Prior chemotherapy , immunotherapy , experimental drug ( FDAapproved drug ) within 3 week . Patients eligible day 1 chemotherapy initiate 3 week prior study entry patient recovery blood count acute toxicity chemotherapy describe inclusion criterion # 3 . 8 . Use nitrosourea ( carmustine ( BCNU ) , lomustine ( CCNU ) mitomycin C within 6 week study entry . 9 . Prior surgery Radiation Therapy ( RT ) within 2 week study entry . 10 . Patients history prior whole pelvic radiation exclude unless prior history severe thrombocytopenia ( i.e . platelet nadir &lt; 10,000/mm^3 ) 11 . Patients history prior high dose chemotherapy stem cell transplant history prolong thrombocytopenia ( &gt; /= 2 week ) . 12 . History platelet disorder include Idiopathic thrombocytopenic purpura ( ITP ) , Thrombotic thrombocytopenic purpura ( TTP ) bleed disorder . 13 . History &gt; 4 prior chemotherapy regimen ( platinum regimen count one regimen ) . 14 . Patients significant bowel dysfunction secondary tumor ( significant abdominal pain severe constipation/diarrhea ( &gt; /= Grade 3 ) , significant difficulty maintain oral nutrition ) . 15 . Patients preexist neuropathy &gt; Grade 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>Advanced Malignancy</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>AMG 531</keyword>
	<keyword>Romiplostim</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Platelets</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Rubex</keyword>
	<keyword>Ifosfamide</keyword>
	<keyword>Ifex</keyword>
</DOC>